Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0O1PU
|
||||
| Former ID |
DIB002232
|
||||
| Drug Name |
BAY-39-9624
|
||||
| Indication | Osteoporosis [ICD9: 733.0, V07.4; ICD10:M80-M81, Z79.890] | Terminated | [1] | ||
| Company |
Bayer AG
|
||||
| Target and Pathway | |||||
| Target(s) | Progesterone receptor | Target Info | Agonist | [2] | |
| KEGG Pathway | Oocyte meiosis | ||||
| Progesterone-mediated oocyte maturation | |||||
| Pathway Interaction Database | Cellular roles of Anthrax toxin | ||||
| Reactome | Nuclear signaling by ERBB4 | ||||
| Nuclear Receptor transcription pathway | |||||
| WikiPathways | Ovarian Infertility Genes | ||||
| Signaling by ERBB4 | |||||
| Nuclear Receptors | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014491) | ||||
| REF 2 | Bayer is seeking an exclusive licensee for its end-of-Phase I progestinagonist Bay 39-9624. Thepharmaletter. 29-04-2002. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.